{"analyses":[{"ciLowerLimit":"-0.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.10","estimateComment":"Analysis stratified by region, prior biologic use, rheumatoid factor (RF) status, and treatment.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8156","paramType":"Weighted Difference","paramValue":"-0.01","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false},{"ciLowerLimit":"-0.05","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.19","estimateComment":"Analysis stratified by region, prior biologic use, RF status, and treatment.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2419","paramType":"Weighted Difference","paramValue":"0.07","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.0","upperLimit":"72.0","value":"64.2"},{"groupId":"OG001","lowerLimit":"55.0","upperLimit":"72.0","value":"63.9"},{"groupId":"OG002","lowerLimit":"63.0","upperLimit":"81.0","value":"72.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"ACR20 defined as overall score of ≥20 in ACR number (ACRn) calculation. Overall score defined as lowest percent improvement from baseline (BL) of following 3 measures: tender joint count (TJC; 68 joints), swollen joint count (SJC: 66 joints), and the 3rd lowest improvement achieved by at least 3 of 5 remaining ACR core parameters: physician's global assessment of disease activity, participant's global assessment of disease activity, participant's assessment of pain (visual analog assessment \\[VAS\\]), Health Assessment Questionnaire (HAQ), and C-Reactive Protein (CRP). If CRP missing, erythrocyte sedimentation rate (ESR) was used. In order for improvements in the ACRn score to be expressed as a positive result, rather than the negative changes that improvements represent, the final ACRn results were multiplied by negative 1. Last observation carried forward (LOCF) for TJC/SJC, HAQ, CRP/ESR, VAS. If change in CRP incalculable, change in ESR used. ACR20 set to Non-Responder if ACRn missing","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received rituximab, 0.5 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG000","title":"Rituximab Low Dose + Methotrexate"},{"description":"Participants received rituximab, 0.5 g, IV, on Days 1 and 15 and 1.0 g, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG001","title":"Rituximab Escalated Dose + Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG002","title":"Rituximab High Dose + Methotrexate"}],"paramType":"NUMBER","populationDescription":"ITT-M2 population","reportingStatus":"POSTED","timeFrame":"Week 48","title":"Percentage of Participants With a Response as Determined by American College of Rheumatology (ACR) 20% Improvement (ACR20)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}